INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY

Special Edition 2014, Issue 1, Part 1.

Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore interviews Dr. David Nelson from the University of Florida about patients who have genotype 3 or cirrhosis, are interferon-ineligible/intolerant, or have failed previous therapy.

Pulmonary exacerbations: diagnoses, and therapeutic regimens

Volume 5, Issue 2.

In this podcast Dr. Patrick Flume, Professor of Medicine and Pediatrics at the Medical University of South Carolina in Charleston, discusses pulmonary exacerbation. He provides patient case scenarios to understand the importance of pulmonary exacerbation and the ability to identify when it occurs.

ROLE OF GLP-1 RECEPTOR AGONISTS IN THE TREATMENT CONTINUUM OF TYPE 2 DIABETES

Volume 1, Issue 8.

Rajesh Garg, MD, Assistant Professor of Medicine, covers the important topic of the role of GLP-1 Receptor Agonists in the Treatment Continuum of Type 2 Diabetes in the format of case-study scenarios for the clinical practice.

Strategies and Devices for Improving Self-Monitoring

Volume 1, Issue 6.

Susan Porter, MSN, CRNP, CDE, Clinical Nurse Practitioner and Certified Diabetes Educator, covers the important topic of strategies and devices for improving self-monitoring in the format of case-study scenarios for the clinical practice.

Women and HIV

Volume 2, Issue 2.

Jean Anderson, MD, Professor of Gynecology and Obstetrics, and Medicine, and Jenell Coleman, MD, Assistant Professor of Gynecology and Obstetrics, and Medicine at the Johns Hopkins University School of Medicine discuss the important topic of Women and HIV in the format of case-study scenarios for the clinical practice.

Highlights from the 2014 EASL Meeting

Volume 3, Issue 12.

Mark S. Sulkowski, MD, Professor of Medicine, Medical Director, Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology at the Johns Hopkins University School of Medicine, Raymond T. Chung, Associate Professor of Medicine, Harvard Medical School, Director of Hepatology, Vice Chief of Gastroenterology at Massachusetts General Hospital, and Laurent Castera, MD, PhD, Department of Hepatology, Beaujon Hospital, AP-AP, INSERM U773 at the University of Paris-Diderot. Discuss new information presented at the 2014 European Association for the Study of the Liver (EASL) meeting, as well as non-invasive markers of liver disease.

CVD RISK FACTORS IN PATIENTS WITH T2D

Volume 1, Issue 4.

Om Ganda, MD, Associate Professor of Medicine at Harvard Medical School, and Senior Physician and Director, Lipid Clinic, and Chair, Clinical Oversight Committee at the Joslin Diabetes Center in Boston, Massachusetts discusses the important topic of CVD risk factors in patients with T2D in the format of case-study scenarios for the clinical practice.